BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34168032)

  • 1. Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial.
    Hoffmann-Vold AM; Fretheim HH; Sarna VK; Barua I; Carstens MN; Distler O; Khanna D; Volkmann ER; Midtvedt Ø; Didriksen H; Dhainaut A; Halse AK; Bakland G; Pesonen M; Olsen I; Molberg Ø
    BMJ Open; 2021 Jun; 11(6):e048541. PubMed ID: 34168032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.
    Fretheim H; Chung BK; Didriksen H; Bækkevold ES; Midtvedt Ø; Brunborg C; Holm K; Valeur J; Tennøe AH; Garen T; Midtvedt T; Trøseid M; Zarè H; Lund MB; Hov JR; Lundin KEA; Molberg Ø; Hoffmann-Vold AM
    PLoS One; 2020; 15(5):e0232739. PubMed ID: 32437393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of faecal microbiota transplantation on the small intestinal mucosa in systemic sclerosis.
    Strahm N; Didriksen H; Fretheim H; Molberg Ø; Midtvedt Ø; Farstad IN; Midtvedt T; Lundin KEA; Aabakken L; Błyszczuk P; Distler O; Kania G; Hoffmann-Vold AM
    Rheumatology (Oxford); 2023 Aug; 62(8):2918-2929. PubMed ID: 36688692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial.
    Pai N; Popov J; Hill L; Hartung E
    BMJ Open; 2019 Nov; 9(11):e030120. PubMed ID: 31784432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder.
    Chen Y; Xueying Z; Jiaqu C; Qiyi C; Huanlong Q; Ning L; Yasong D; Xiaoxin Z; Rong Y; Jubao L; Xiaoqiong L; Chunlian M; Yu W; Shidong C; Guifang K; Dongmei Z; Shuanfeng F; Xujing Z; Binrang Y; Yanxia W; Ling L; Song Y; Xiang Z; Beihua Z; Lin J; Hong J;
    BMJ Open; 2022 Jan; 12(1):e051613. PubMed ID: 35105621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
    Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
    J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.
    Jitsumura M; Cunningham AL; Hitchings MD; Islam S; Davies AP; Row PE; Riddell AD; Kinross J; Wilkinson TS; Jenkins GJ; Williams JG; Harris DA
    BMJ Open; 2018 Oct; 8(10):e021987. PubMed ID: 30341117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial.
    Skjevling L; Goll R; Hanssen HM; Johnsen PH
    BMJ Open; 2024 Jun; 14(6):e073275. PubMed ID: 38858151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial.
    Marighela TF; Arismendi MI; Marvulle V; Brunialti MKC; Salomão R; Kayser C
    Rheumatology (Oxford); 2019 Nov; 58(11):1985-1990. PubMed ID: 31056685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis.
    Quraishi MNN; Yalchin M; Blackwell C; Segal J; Sharma N; Hawkey P; McCune V; Hart AL; Gaya D; Ives NJ; Magill L; Loi S; Hewitt C; Gerasimidis K; Loman NJ; Hansen R; McMullan C; Mathers J; Quince C; Crees N; Iqbal T
    BMJ Open; 2019 Nov; 9(11):e030659. PubMed ID: 31719078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study.
    Mazzawi T; Hausken T; Refsnes PF; Hatlebakk JG; Lied GA
    Microorganisms; 2022 Sep; 10(9):. PubMed ID: 36144420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial.
    Pai N; Popov J
    BMJ Open; 2017 Aug; 7(8):e016698. PubMed ID: 28827258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study.
    Verburgt CM; Dunn KA; Otley A; Heyman MB; Verstraete S; Sunseri W; Sylvester F; de Meij T; Comeau A; Langille M; de Jonge WJ; Benninga MA; Van Limbergen JE
    BMJ Open; 2023 Feb; 13(2):e064944. PubMed ID: 36725090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial.
    Kragsnaes MS; Kjeldsen J; Horn HC; Munk HL; Pedersen FM; Holt HM; Pedersen JK; Holm DK; Glerup H; Andersen V; Fredberg U; Kristiansen K; Christensen R; Ellingsen T
    BMJ Open; 2018 Apr; 8(4):e019231. PubMed ID: 29703851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
    Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
    Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.